Latest Industry Insights

In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to find out more about the company’s mission, its science and its vision for the future of neuroscience drug development.

In this interview, Felix Spira, senior manager at Molecular Devices, discusses how automation and AI improve brain organoid cultivation, enabling consistent long-term models that advance research into complex neurodegenerative diseases.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

In this interview, Dr. Iain Yisu Wang from MedChemExpress discusses the growing role of AI, the value of phenotypic screening and how tailored compound libraries are helping researchers keep up with the increasing complexity of drug discovery.

From AI to digital laboratories, discover how new technologies are shaping the future of science at Lab of the Future Europe 2025.

As global scientific and regulatory landscapes shift, companies across the life sciences sector are under growing pressure to adapt. Hear how Phenomenex are taking a proactive approach.

Illumina’s Rami Mehio discusses the whole-genome sequencing of 490,640 UK Biobank participants with Molly Coddington for Technology Networks.

This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.

In this article, discover how the FDA and NIH are replacing animal testing with human models, such as organoids, featuring expert insights on safer, faster and ethical drug development.

Discover how AI-powered ADMET modeling can enable the prediction of toxicity and pharmacokinetics with depth, transparency and scientific rigor.